ACADIA Pharmaceuticals Inc
(NAS:ACAD)
$
16.95
-0.42 (-2.42%)
Market Cap: 2.89 Bil
Enterprise Value: 2.37 Bil
PE Ratio: 22.27
PB Ratio: 5.01
GF Score: 75/100 ACADIA Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2022 / 03:10PM GMT
Release Date Price:
$16.9
(-5.64%)
Jeff Hung
Morgan Stanley, Research Division - Equity Analyst
Good morning, and welcome to the Morgan Stanley Global Healthcare Conference. I'm Jeff Hung, one of the biotech analysts. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. For this session, we have ACADIA Pharmaceuticals with CEO, Steve Davis; and CFO, Mark Schneyer. Welcome, Steve, Mark.
Stephen R. Davis
ACADIA Pharmaceuticals Inc. - CEO & Director
Thank you.
Mark C. Schneyer
ACADIA Pharmaceuticals Inc. - Executive VP & CFO
Thanks, Jeff.
Questions & Answers
Jeff Hung
Morgan Stanley, Research Division - Equity Analyst
So maybe let's start with NUPLAZID in PDP. With 2Q earnings, you reduced the top end of your net sales guidance range.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot